• Peter J. Barnes
Part of the Progress in Inflammation Research book series (PIR)


Corticosteroids are the most effective therapy currently available for asthma and improvement with corticosteroids is one of the hallmarks of asthma. Inhaled glucocorticoids have revolutionised asthma treatment and have now become the mainstay of therapy for patients with chronic disease [1]. There has recently been an enormous increase in our understanding of the molecular mechanisms whereby glucocorticoids suppress inflammation in asthma and this has led to changes in the way corticosteroids are used and may point the way to the development of more specific therapies in the future [2, 3].


Glucocorticoid Receptor Allergy Clin Immunol Oral Corticosteroid Respir Crit Secretory Leukocyte Protease Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Barnes PJ (1995) Inhaled glucocorticoids for asthma. New Engl J Med 332: 868–875PubMedCrossRefGoogle Scholar
  2. 2.
    Barnes PJ (1996) Molecular mechanisms of steroid action in asthma. J Allergy Clin Immunol 97: 159–168PubMedCrossRefGoogle Scholar
  3. 3.
    Barnes PJ (1996) Mechanism of action of glucocorticoids in asthma. Am J Respir Crit Care Med 154: S21–S27PubMedGoogle Scholar
  4. 4.
    Barnes PJ Adcock IM (1993) Anti-inflammatory actions of steroids: molecular mechanisms. Trends Pharmacol Sci 14: 436–441PubMedCrossRefGoogle Scholar
  5. 5.
    Barnes PJ (1998) Antiinflammatory actions of glucocorticosteroids: molecular mechanisms. Clin Sci 94: 557–572PubMedGoogle Scholar
  6. 6.
    Bamberger CM, Bamberger AM, deCastro M, Chrousos GP (1995) Glucocorticoid receptor β, a potential endogenous inhibitor of glucocorticoid action in humans. J Clin Invest 95: 2435–2441PubMedCrossRefGoogle Scholar
  7. 7.
    Muller M, Renkawitz R (1991) The glucocorticoid receptor. Biochim Biophys Aeta 1088: 171–182CrossRefGoogle Scholar
  8. 8.
    Encio PJ, Detgra-Wadleigh SD (1991) The genomic structure of the human glucocorticoid receptor. J Biol Chem 266: 7182–7188PubMedGoogle Scholar
  9. 9.
    Heck S, Kullmann M, Grast A, Ponta H, Rahmsdorf HJ, Herrlich P Cato ACB (1994) A distinct modulating domain in glucocorticoid receptor monomers in the repression of activity of the transcription factor AP-1. EMBO J 1994 13: 4087–4095PubMedGoogle Scholar
  10. 10.
    Gronemeyer H (1992) Control of transcription activation by steroid hormone receptors. FASEB J 6(8): 2524–2529PubMedGoogle Scholar
  11. 11.
    Beato M, Herrlich P, Schutz G (1995) Steroid hormone receptors: many actors in search of a plot. Cell 83: 851–857PubMedCrossRefGoogle Scholar
  12. 12.
    Yang-Yen H, Chambard J, Sun Y, SmealT, Schmidt TJ, Drovin J, Karin M (1990) Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction. Cell 62: 1205–1215PubMedCrossRefGoogle Scholar
  13. 13.
    Adcock IM, Shirasaki H, Gelder CM, Peters MJ, Brown CR, Barnes PJ (1994) The effects of glucocorticoids on phorbol ester and cytokine stimulated transcription factor activation in human lung. Life Sci 55: 1147–1153PubMedCrossRefGoogle Scholar
  14. 14.
    Adcock IM, Brown CR, Gelder CM, Shirasaki H, Peters MJ, Barnes PJ (1995) The effects of glucocorticoids on transcription factor activation in human peripheral blood mononuclear cells. Am J Physiol 37: C331–C338Google Scholar
  15. 15.
    Ray A Prefontaine KE (1994) Physical association and functional antagonism between the p65 subunit of transcription factor NF-kB and the glucocorticoid receptor. Proc Natl Acad Sci USA 91: 752–756PubMedCrossRefGoogle Scholar
  16. 16.
    Scheinman RI, Gualberto A, Jewell CM, Cidlowski JA, Baldwin AS (1996) Characterization of the mechanisms involved in transrepression of NF-κB by activated glucocorticoid receptors. Mol Cell Biol 15: 943–953Google Scholar
  17. 17.
    Caldenhoven E, Liden J, Wissink S, Van De Stolpe A, Raaijmakers J, Koenderman L, Okret S, Gustafsson J, van der Saag P (1995) Negative cross-talk between RelA and the glucocorticoid receptor: a possible mechanism for the antiinflammatory action of glucocorticoids. Mol Endocrinol 9: 401–412PubMedCrossRefGoogle Scholar
  18. 18.
    Imai F, Minger JN, Mitchell JA, Yamamoto KR, Granner DK (1993) Glucocorticoid receptor-cAMP response element-binding protein interaction and the response of the phosphoenolpyruvate carboxykinase gene to glucocorticoids. J Biol Chem 268: 5353–5356PubMedGoogle Scholar
  19. 19.
    Adcock IM, Barnes PJ (1996) Tumour necrosis factor-a causes retention of activated glucocorticoid receptor within the cytoplasm of A549 cells. Biochem Biophys Res Commun 225: 1127–1132CrossRefGoogle Scholar
  20. 20.
    Janknecht R, Hunter T (1996) A growing coactivator network. Nature 383: 22–23PubMedCrossRefGoogle Scholar
  21. 21.
    Kamei Y, Xu L, Heinzel T et al (1996) A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 85: 403–414PubMedCrossRefGoogle Scholar
  22. 22.
    Smith CL, Onate SA, Tsai MJ, O’Malley BW (1996) CREB binding protein acts synergistically with steroid receptor coactivator-1 to enhance steroid receptor-dependent transcription. Proc Natl Acad Sci USA 93: 8884–8888PubMedCrossRefGoogle Scholar
  23. 23.
    Yao TP, Ku G, Zhou N, Scully R, Livingston DM (1996) The nuclear hormone receptor coactivator SRC-1 is a specific target of p300. Proc Natl Acad Sci USA 93: 10626–10631PubMedCrossRefGoogle Scholar
  24. 24.
    Hong H, Kohli K, Garabedian MJ, Stallcup MR (1997) GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors. Mol Cell Biol 17: 2735–2744PubMedGoogle Scholar
  25. 25.
    Ogryzko W, Schiltz RL, Russanova V, Howard BH, Nakatani Y (1996) The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87: 953–959PubMedCrossRefGoogle Scholar
  26. 26.
    Wolffe AP (1997) Sinful repression. Nature 387: 16–17PubMedCrossRefGoogle Scholar
  27. 27.
    Nagy L, Kao HY, Chakravarti D, Lin RJ, Hassig CA, Ayer DE, Schreiber SL, Evans RM (1997) Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 89: 373–380PubMedCrossRefGoogle Scholar
  28. 28.
    Heinzel T, Lavinsky RM, Mullen TM et al (1997) A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature 387: 43–48PubMedCrossRefGoogle Scholar
  29. 29.
    Flower RJ Rothwell NJ (1994) Lipocortin-1: cellular mechanisms and clinical relevance. Trends Pharmacol Sci 15: 71–76PubMedCrossRefGoogle Scholar
  30. 30.
    Abbinante-Nissen JM, Simpson LG, Leikauf GD (1995) Corticosteroids increase secretory leukocyte protease inhibitor transcript levels in airway epithelial cells. Am J Physiol 12: L601–L606Google Scholar
  31. 31.
    Levine SJ, Benfield T, Shelhamer JH (1996) Corticosteroids induce intracellular interleukin-1 receptor antagonist type I expression by a human airway epithelial cell line. Am J Respir Cell Mol Biol 15: 245–251PubMedGoogle Scholar
  32. 32.
    Sousa AR, Lane SJ, Nakhosteen JA, Lee TH, Poston RN (1996) Expression of interleukin-1 beta (IL-1b) and interleukin-1 receptor antagonist (IL-1ra) on asthmatic bronchial epithelium. Am J Respir Crit Care Med 154: 1061–1066PubMedGoogle Scholar
  33. 33.
    Colotta F, Re F, Muzio M, Bertini R, Polentarutti N, Sironi M, Giri JG, Dower SK, Sims JE, Mantovani A (1993) Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science 261(5120): 472–475PubMedCrossRefGoogle Scholar
  34. 34.
    Wang P, Wu P, Siegel MI, Egan RW, Billah MM (1995) Interleukin (IL)-10 inhibits nuclear factor kappa B activation in human monocytes. IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J Biol Chem 270: 9558–9563PubMedCrossRefGoogle Scholar
  35. 35.
    Borish L, Aarons A, Rumbyrt J, Cvietusa P, Negri J, Wenzel S (1996) Interleukin-10 regulation in normal subjects and patients with asthma. J Allergy Clin Immunol 97: 1288–1296PubMedCrossRefGoogle Scholar
  36. 36.
    John M, Lim S, Seybold J, Robichaud A, O’Connor B, Barnes PJ, Chung KF (1998) Inhaled corticosteroids increase IL-10 but reduce MIP-1α, GM-CSF and IFNγ release from alveolar macrophages in asthma. Am J Respir Crit Care Med 157: 256–262PubMedGoogle Scholar
  37. 37.
    Barnes PJ, Karin M (1997) Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. New Engl J Med 336: 1066–1071PubMedCrossRefGoogle Scholar
  38. 38.
    Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M (1995) Immunosuppression by glucocorticoids: inhibition of NF-αB activity through induction of IκB synthesis. Science 270: 286–290PubMedCrossRefGoogle Scholar
  39. 39.
    Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS (1995) Role of transcriptional activation of IκBa in mediating immunosuppression by glucocorticoids. Science 270: 283–286PubMedCrossRefGoogle Scholar
  40. 40.
    Brostjan C, Anrather J, Csizmadia V, Stoka D, Soares M, Bach FH, Winkler H (1996) Glucocorticoid-mediated repression of NFκB activity in endothelial cells does not involve induction of IkBa synthesis. J Biol Chem 271: 19612–19616PubMedCrossRefGoogle Scholar
  41. 41.
    Newton R, Hart LA, Stevens DA, Bergmann M, Donnelly LE, Adcock IM, Barnes PJ (1998) Effect of dexamethasone on interleukin-1β-(IL-1β)-induced nuclear factor-κB (NF-κB) and κB-dependent transcription in epithelial cells. Eur J Biochem 254: 81–89PubMedCrossRefGoogle Scholar
  42. 42.
    Heck S, Bender K, Kullmann M, Gottlicher M, Herrlich P Cato AC (1997) IκBα-independent downregulation of NF-κB activity by glucocorticoid receptor. EMBO J 16: 4698–4707PubMedCrossRefGoogle Scholar
  43. 43.
    Borson DB, Jew S, Gruenert DC (1991) Glucocorticoids induce neutral endopeptidase in transformed human trachea epithelial cells. Am J Physiol 260: L83–L89PubMedGoogle Scholar
  44. 44.
    Sont JK, van Krieken JH, van Klink HC, Roldaan AC, Apap CR, Willems LN, Sterk PJ (1997) Enhanced expression of neutral endopeptidase (NEP) in airway epithelium in biopsies from steroid-versus nonsteroid-treated patients with atopic asthma. Am J Respir Cell Mol Biol 16: 549–556PubMedGoogle Scholar
  45. 45.
    Collins S, Caron MG, Lefkowitz RJ (1988) β-Adrenergic receptors in hamster smooth muscle cells are transcriptionally regulated by glucocorticoids. J Biol Chem 263: 9067–9070PubMedGoogle Scholar
  46. 46.
    Mak JCW, Nishikawa M, Barnes PJ (1995) Glucocorticosteroids increase β2-adrenergic receptor transcription in human lung. Am J Physiol 12: L41–L46Google Scholar
  47. 47.
    Mak JCW, Nishikawa M, Shirasaki H, Miyayasu K, Barnes PJ (1995) Protective effects of a glucocorticoid on down-regulation of pulmonary β2-adrenergic receptors in vivo. J Clin Invest 96: 99–106PubMedCrossRefGoogle Scholar
  48. 48.
    Northrop JP, Ullman KS, Crabtree GR (1993) Characterization of the nuclear and cytoplasmic components of the lymphoid-specific nuclear factor of activated T cells (NF-AT). J Biol Chem 268: 2917–2923PubMedGoogle Scholar
  49. 49.
    Paliogianni F, Raptis A, Ahuja SS, Najjar SM, Boumpas DT (1993) Negative transcriptional regulation of human interleukin 2 (IL-2) gene by glucocorticoids through interference with nuclear transcription factors AP-1 and NF-AT. J Clin Invest 91: 1481–1489PubMedCrossRefGoogle Scholar
  50. 50.
    Linden M, Brattsand R (1994) Effects of a corticosteroid, budesonide, on alveolar macrophages and blood monocyte secretion of cytokines: differential sensitivity of GM-CSF, IL-1b and IL-6. Pulm Pharmacol 7: 43–47PubMedCrossRefGoogle Scholar
  51. 51.
    Robbins RA, Barnes PJ, Springall DR, Warren JB, Kwon OJ, Buttery LDK, Wilson AJ, Geller DA, Polak JM. Expression of inducible nitric oxide synthase in human bronchial epithelial cells. Biochem Biophys Res Commun 1994 203: 209–218Google Scholar
  52. 52.
    Xie Q, Kashiwarbara Y, Nathan C (1994) Role of transcription factor NF-κB/Rel in induction of nitric oxide synthase. J Biol Chem 269: 4705–4708PubMedGoogle Scholar
  53. 53.
    Mitchell JA, Belvisi MG, Akarasereemom P, Robbins RA, Kowon OJ, Croxtell J, Barnes PJ, Vane JR (1994) Induction of cyclo-oxygenase-2 by cytokines in human pulmonary epithelial cells: regulation by dexamethasone. Br J Pharmacol 113: 1008–1014PubMedCrossRefGoogle Scholar
  54. 54.
    Yamamoto K, Arakawa T, Ueda N, Yamamoto S (1995) Transcriptional roles of nuclear factor kB and nuclear factor-interleukin 6 in the tumor necrosis-a-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. J Biol Chem 270: 31315–31320PubMedCrossRefGoogle Scholar
  55. 55.
    Newton R, Kuitert LM, Bergmann M, Adcock IM, Barnes PJ (1997) Evidence for involvement of NF-κB in the transcriptional control of COX-2 gene expression by IL-1β. Biochem Biophys Res Commun 237: 28–32PubMedCrossRefGoogle Scholar
  56. 56.
    Newton R, Kuitert LM, Slater DM, Adcock IM, Barnes PJ (1997) Induction of cPLA2 and COX-2 mRNA by proinflammatory cytokines is suppressed by dexamethasone in human airway epitheial cells. Life Sci 60: 67–78PubMedCrossRefGoogle Scholar
  57. 57.
    Vittori E, Marini M, Fasoli A, de Franchis R, Mattoli S (1992) Increased expression of endothelin in bronchial epithelial cells of asthmatic patients and effect of corticosteroids. Am Rev Respir Dis 1461: 1320–1325Google Scholar
  58. 58.
    Adcock IM, Peters M, Gelder C, Shirasaki H, Brown CR, Barnes PJ (1993) Increased tachykinin receptor gene expression in asthmatic lung and its modulation by steroids. J Mol Endocrinol 11: 1–7PubMedCrossRefGoogle Scholar
  59. 59.
    Ihara H, Nakanishi S (1990) Selective inhibition of expression of the substance P receptor mRNA in pancreatic acinar AR42J cells by glucocorticoids. J Biol Chem 36: 22441–22445Google Scholar
  60. 60.
    Katsunuma T, Mak JCW, Barnes PJ (1998) Glucocorticoids reduce tachykinin NK2-receptor expression in bovine tracheal smooth muscle. Eur J Pharmacol; in press Google Scholar
  61. 61.
    Owens GP, Hahn WE, Cohen JJ (1991) Identification of mRNAs associated with programmed cell death in immature thymocytes. Mol Cell Biol 11: 4177–4188PubMedGoogle Scholar
  62. 62.
    Cronstein BN, Kimmel SC, Levin RI, Martiniuk F, Weissmann G (1992) A mechanism for the antiinflammatory effects of corticosteroids: The glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proc Natl Acad Sci USA 89: 9991–9995PubMedCrossRefGoogle Scholar
  63. 63.
    Van De Stolpe A, Caldenhoven E, Raaijmakers JAM, Van Der Saag PT, Koendorman L (1993) Glucocorticoid-mediated repression of intercellular adhesion molecule-1 expression in human monocytic and bronchial epithelial cell lines. Am J Respir Cell Mol Biol 8: 340–347PubMedGoogle Scholar
  64. 64.
    Bergstrand H, Björnson A, Blaschuke E, Brattsand R, Eklund A, Larsson K, Linden M (1990) Effects of an inhaled corticosteroid, budesonide, on alveolar macrophage function in smokers. Thorax 45: 362–368PubMedCrossRefGoogle Scholar
  65. 65.
    Standiford TJ, Kunkel SL, Rolfe MW, Evanoff HL, Allen RM, Srieter RW (1992) Regulation of human alveolar macrophage and blood monocyte-derived interleukin-8 by prostaglandin E2 and dexamethasone. Am J Respir Cell Mol Biol 6: 75–81PubMedGoogle Scholar
  66. 66.
    Borish L, Mascali JJ, Dishuck J, Beam WR, Martin RJ, Rosenwasser LJ (1992) Detection of alveolar macrophage-derived IL-1β in asthma. Inhibition with corticosteroids. J Immunol 149: 3078–3082PubMedGoogle Scholar
  67. 67.
    Kita H, Abu-Ghazaleh R, Sanderson CJ, Gleich GJ (1991) Effect of steroids on immunoglobulin-induced eosinophil degranulation. J Allergy Clin Immunol 87: 70–77PubMedCrossRefGoogle Scholar
  68. 68.
    Lamas AM, Leon OG, Schleimer RP (1991) Glucocorticoids inhibit eosinophil responses to granulocyte-macrophage colony-stimulating factor. J Immunol 147: 254–259PubMedGoogle Scholar
  69. 69.
    Wallen N, Kita H, Weiller D, Gleich GJ (1991) Glucocorticoids inhibit cytokine-mediated eosinophil survival. J Immunol 147: 3490–3495PubMedGoogle Scholar
  70. 70.
    Wempe JB, Tammeling EP, Köeter GH, Haransson L, Venge P, Postma DS (1992) Blood eosinophil numbers and activity during 24 hours effects of treatment with budesonide and bambuterol. J Allergy Clin Immunol 90: 757–765PubMedCrossRefGoogle Scholar
  71. 71.
    Evans PM, O’Connor BJ, Fuller RW, Barnes PJ, Chung KF (1993) Effect of inhaled corticosteroids on peripheral eosinophil counts and density profiles in asthma. J Allergy Clin Immunol 91: 643–649PubMedCrossRefGoogle Scholar
  72. 72.
    Rolfe FG, Hughes JM, Armour CL, Sewell WA (1992) Inhibition of interleukin-5 gene expression by dexamethasone. Immunology 77: 494–499PubMedGoogle Scholar
  73. 73.
    Cohan VL, Undem BJ, Fox CC, Adkinson NF, Lichtenstein LM, Schleimer RP (1989) Dexamethasone does not inhibit the release of mediators from human lung mast cells residing in airway, intestine or skin. Am Rev Respir Dis 140: 951–954PubMedGoogle Scholar
  74. 74.
    Laitinen LA, Laitinen A, Haahtela T (1992) A comparative study of the effects of an inhaled corticosteroid, budesonide, and of a β2 agonist, terbutaline, on airway inflammation in newly diagnosed asthma. J Allery Clin Immunol 90: 32–42CrossRefGoogle Scholar
  75. 75.
    Djukanovic R, Wilson JW, Britten YM, Wilson SJ, Walls AF, Poche WF, Howarth PH, Holgate ST (1992) Effect of an inhaled corticosteroid on airway inflammation and symptoms of asthma. Am Rev Respir Dis 145: 669–674PubMedGoogle Scholar
  76. 76.
    Holt PG. Regulation of antigen-presenting cell function(s) in lung and airway tissues. Eur Resp J 1993 6: 120–129Google Scholar
  77. 77.
    Nelson DJ, McWilliam AS, Haining S, Holt PG (1995) Modulation of airway intraepithelial dendritic cells following exposure to steroids. Am J Respir Crit Care Med 151: 475–481PubMedGoogle Scholar
  78. 78.
    Holm AF, Fokkens WJ, Godthelp T, Mulder PG, Vroom TM, Rinjntjes E (1995) Effect of 3 months’ nasal steroid therapy on nasal T cells and Langerhans cells in patients suffering from allergic rhinitis. Allergy 50: 204–209PubMedCrossRefGoogle Scholar
  79. 79.
    Cox G (1995) Glucocorticoid treatment inhibits apoptosis in human neutrophils. J Immunol 193: 4719–4725Google Scholar
  80. 80.
    Boschetto P, Rogers DF, Fabbri LM, Barnes PJ (1991) Corticosteroid inhibition of airway microvascular leakage. Am Rev Respir Dis 143: 605–609PubMedGoogle Scholar
  81. 81.
    Erjefalt I, Persson CGA (1991) Pharmacologic control of plasma exudation into tracheobronchial airways. Am Rev Respir Dis 143: 1008–1014PubMedGoogle Scholar
  82. 82.
    Carnuccio R, Di Rosa M, Guerrasio B, Iuvone T, Satebin L (1987) Vasocortin: a novel glucocorticoid-induced anti-inflammatory protein. Br J Pharmacol 90: 443–445PubMedCrossRefGoogle Scholar
  83. 83.
    Van de Graaf EA, Out TA, Loos CM, Jansen HM (1991) Respiratory membrane permeability and bronchial hyperreactivity in patients with stable asthma. Am Rev Respir Dis 143: 362–368PubMedGoogle Scholar
  84. 84.
    Devalia JL, Wang JH, Sapsford RJ, Davies RJ (1994) Expression of RANTES in human bronchial epithelial cells and the effect of beclomethasone diproprionate (BDP). Eur Resp J 7 (Suppl 18): 98SGoogle Scholar
  85. 85.
    Levine SJ (1995) Bronchial epithelial cell-cytokine interactions in airway epithelium. J Invest Med 43: 241–249Google Scholar
  86. 86.
    Schweibert LM, Stellato C, Schleimer RP (1996) The epithelium as a target for glucocorticoid action in the treatment of asthma. Am J Respir Crit Care Med 154: S16–S20Google Scholar
  87. 87.
    Kwon OJ, Au BT, Collins PD, Baraniuk JN, Adcock IM, Chung KF, Barnes PJ (1994) Inhibition of interleukin-8 expression in human cultured airway epithelial cells. Immunology 81: 389–394PubMedGoogle Scholar
  88. 88.
    Kwon OJ, Au BT, Collins PD, Adcock IM, Mak JC, Robbins RA, Baraniuk JM, Chung KF, Barnes PJ (1994) Tumor necrosis factor-induced interleukin 8 expression in cultured human epithelial cells. Am J Physiol 11: L398–L405Google Scholar
  89. 89.
    Kwon OJ, Jose PJ, Robbins RA, Schall TJ, Williams TJ, Barnes PJ (1995) Glucocorticoid inhibition of RANTES expression in human lung epithelial cells. Am J Respir Cell Mol Biol 12: 488–496PubMedGoogle Scholar
  90. 90.
    Sousa AR, Poston RN, Lane SJ, Narhosteen JA, Lee TH (1993) Detection of GM-CSF in asthmatic bronchial epithelium and decrease by inhaled corticosteroids. Am Rev Respir Dis 147: 1557–1561PubMedGoogle Scholar
  91. 91.
    Trigg CJ, Manolistas ND, Wang J et al (1994) Placebo-controlled immunopathological study of four months inhaled corticosteroids in asthma. Am J Respir Crit Care Med 150: 17–22PubMedGoogle Scholar
  92. 92.
    Hamid Q, Springall DR, Riveros-Moreno V, Chanez P, Howarth P, Redington A, Bousquet J, Godard P, Holgate S, Polak J (1993) Induction of nitric oxide synthase in asthma. Lancet 342: 1510–1513PubMedCrossRefGoogle Scholar
  93. 93.
    Kharitonov SA, Yates D, Robbins RA, Logan-Sinclair R, Shinebourne E, Barnes PJ (1994) Increased nitric oxide in exhaled air of asthmatic patients. Lancet 343: 133–135PubMedCrossRefGoogle Scholar
  94. 94.
    Yates DH, Kharitonov SA, Robbins RA, Thomas PS, Barnes PJ (1995) Effect of a nitric oxide synthase inhibitor and a glucocorticosteroid on exhaled nitric oxide. Am J Resp Crit Care Med 152: 892–896PubMedGoogle Scholar
  95. 95.
    Kharitonov SA, Yates DH, Barnes PJ (1996) Regular inhaled budesonide decreases nitric oxide concentration in the exhaled air of asthmatic patients. Am J Resp Crit Care Med 153: 454–457PubMedGoogle Scholar
  96. 96.
    Shimura S, Sasaki T, Ikeda K, Yamauchi K, Sasaki H, Takishima T (1990) Direct inhibitory action of glucocorticoid on glycoconjugate secretion from airway submucosal glands. Am Rev Respir Dis 141: 1044–1099PubMedGoogle Scholar
  97. 97.
    Kai H, Yoshitake K, Hisatsune A, Kido T, Isohama Y, Takahama K, Miyata T (1996) Dexamethasone suppresses mucus production and MUC-2 and MUC-5AC gene expression by NCI-H292 cells. Am J Physiol 271: L484–L488PubMedGoogle Scholar
  98. 98.
    Jeffery PK, Godfrey RW, Ädelroth E, Nelson F, Rogers A, Johansson S (1992) Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. Am Rev Respir Dis 145: 890–899PubMedGoogle Scholar
  99. 99.
    Burke C, Power CK, Norris A, Condez A, Schmekel B, Poulter LW (1992) Lung function and immunopathological changes after inhaled corticosteroid therapy in asthma. Eur Respir J 5: 73–79PubMedGoogle Scholar
  100. 100.
    Ädelroth E, Rosenhall L, Johansson S, Linden M, Venge P (1990) Inflammatory cells and eosinophilic activity in asthmatics investigated by bronchoalveolar lavage. Am Rev Respir Dis 142: 91–99PubMedGoogle Scholar
  101. 101.
    Wilson JW, Djukanovic R, Howarth PH, Holgate ST (1994) Inhaled beclomethasone diproprionate downregulates airway lymphocyte activation in atopic asthma. Am J Respir Crit Care Med 149: 86–90PubMedGoogle Scholar
  102. 102.
    Lungren R, Soderberg M, Horstedt P, Stenling R (1988) Morphological studies on bronchial mucosal biopsies from asthmatics before and after ten years treatment with inhaled steroids. Eur Resp J 1: 883–889Google Scholar
  103. 103.
    Barnes PJ (1990) Effect of corticosteroids on airway hyperresponsiveness. Am Rev Respir Dis 141: S70–S76PubMedGoogle Scholar
  104. 104.
    Bel EH, Timers MC, Zwinderman AH, Dijkman JH, Sterk PJ (1991) The effect of inhaled corticosteroids on the maximal degree of airway narrowing to methacholine. Am Rev Respir Dis 143: 109–113PubMedGoogle Scholar
  105. 105.
    Kamada AK, Szefler SJ, Martin RJ, Boushey HA, Chinchilli VM, Drazen JM, Fish JE, Israel E, Lazarus SC, Lemanske RF (1996) Issues in the use of inhaled steroids. Am J Respir Crit Care Med 153: 1739–1748PubMedGoogle Scholar
  106. 106.
    Reed CE (1990) Aerosol glucocorticoid treatment of asthma: adults. Am Rev Respir Dis 140: S82–S88Google Scholar
  107. 107.
    Barnes PJ (1989) A new approach to asthma therapy. N Engl J Med 321: 1517–1527PubMedCrossRefGoogle Scholar
  108. 108.
    Sheffer AL (1992) International consensus report on diagnosis and management of asthma. Clin Exp Allergy 22 (Suppl 1): 1–72CrossRefGoogle Scholar
  109. 109.
    Global Initiative for Asthma (1995) Global strategy for asthma management and prevention. NHLBI/WHO Workshop Report. Publication 95-3659Google Scholar
  110. 110.
    British Thoracic Society (1997) The British guidelines on asthma management. Thorax 52 (Suppl 1): S1–S21CrossRefGoogle Scholar
  111. 111.
    Haahtela T, Jarvinen M, Kava T et al (1991) Comparison of a β2-agonist terbutaline with an inhaled steroid in newly detected asthma. New Engl J Med 325: 388–392PubMedCrossRefGoogle Scholar
  112. 112.
    Juniper EF, Kline PA, Vanzieleghem MA, Ramsdale EH, O’Byrne PM, Hargreave FE (1990) Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis 142: 832–836PubMedGoogle Scholar
  113. 113.
    Kerrebijn KF, Von Essen-Zandvliet EEM, Neijens HJ (1987) Effect of long-term treatment with inhaled corticosteroids and beta-agonists on bronchial responsiveness in asthmatic children. J Allergy Clin Immunol 79: 653–659PubMedCrossRefGoogle Scholar
  114. 114.
    Vathenen AS, Knox AJ, Wisniewski A, Tattersfield AE (1991) Time course of change in bronchial reactivity with an inhaled corticosteroid in asthma. Am Rev Respir Dis 143: 1317–1321PubMedGoogle Scholar
  115. 115.
    Toogood JH (1989) High dose inhaled steroid therapy for asthma. J Allergy Clin Immunol 83: 528–536PubMedCrossRefGoogle Scholar
  116. 116.
    Salmeron S, Guerin J, Godard P, Renon D, Michel H, Duroux P, Taytard A (1989) High doses of inhaled corticosteroids in unstable chronic asthma. Am Rev Respir Dis 140: 167–171PubMedCrossRefGoogle Scholar
  117. 117.
    Lacronique J, Renon D, Georges D, Henry-Amar M, Marsac J (1991) High-dose beclomehtasone: oral steroid-sparing effect in severe asthmatic patients. Eur Respir J 4: 807–812PubMedGoogle Scholar
  118. 118.
    Dahl R, Pedersen B, Hägglöf B (1989) Nocturnal asthma: effect of treatment with oral sustained-release terbutaline, inhaled budesonide and the two in combination. J Allergy Clin Immunol 83: 811–815PubMedCrossRefGoogle Scholar
  119. 119.
    Wempe JB, Tammeling EP, Postma DS, Auffarth B, Teengs JP, Koëter GH (1992) Effects of budesonide and bambuterol on circadian variation of airway responsiveness and nocturnal asthma symptoms of asthma. J Allergy Clin Immunol 90: 349–357PubMedCrossRefGoogle Scholar
  120. 120.
    Juniper EF, Kline PA, Vanzielegmem MA, Hargreave FE (1991) Reduction of budesonide after a year of increased use: a randomized controlled trial to evaluate whether improvements in airway responsiveness and clinical asthma are maintained. J Allergy Clin Immunol 87: 483–489PubMedCrossRefGoogle Scholar
  121. 121.
    van Essen-Zandvliet EE, Hughes MD, Waalkens HJ, Duiverman EJ, Pocock SJ, Kerrebijn KF (1992) Effects of 22 months of treatment with inhaled corticosteroids and/or beta2-agonists on lung function, airway responsiveness and symptoms in children with asthma. Am Rev Respir Dis 146: 547–554PubMedGoogle Scholar
  122. 122.
    Waalkens HJ, van Essen-Zandvliet EE, Hughes MD, Gerritsen J, Duiverman EJ, Knol K, Kerrebijn KF. Cessation of long-term treatment with inhaled corticosteroids (budesonide) in children with asthma results in deterioration. Am Rev Respir Dis 1993 148: 1252–1257PubMedGoogle Scholar
  123. 123.
    Ilangovan P, Pedersen S, Godfrey S, Nikander K, Novisky N, Warner JO (1993) Nebulised budesonide suspension in severe steroid-dependent preschool asthma. Arch Dis Child 68: 356–359PubMedCrossRefGoogle Scholar
  124. 124.
    Gleeson JGA, Price JF (1988) Controlled trial of budesonide given by Nebuhaler in preschool children with asthma. Br Med J 297: 163–166CrossRefGoogle Scholar
  125. 125.
    Bisgard H, Munck SL, Nielsen JP, Peterson W, Ohlsson SV (1990) Inhaled budesonide for treatment of recurrent wheezing in early childhood. Lancet 336: 649–651CrossRefGoogle Scholar
  126. 126.
    Dompeling E, Van Schayck CP, Molema J, Folgering H, van Grusven PM, van Weel C (1992) Inhaled beclomethasone improves the course of asthma and COPD. Eur Resp J 5: 945–952Google Scholar
  127. 127.
    Haahtela T, Järvinsen M, Kava T et al (1994) Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. New Engl J Med 331: 700–705PubMedCrossRefGoogle Scholar
  128. 128.
    Agertoft L Pedersen S (1994) Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Resp Med 5: 369–372Google Scholar
  129. 129.
    Selroos O, Backman R, Forsen K, Löfroos A, Nieistö M, Pietinalcho A, Riska A (1994) When to start treatment of asthma with inhaled steroids? Eur Resp J 7 (Suppl 18): 151SGoogle Scholar
  130. 130.
    Szefler S (1991) Glucocorticoid therapy for asthma: clinical pharmacology. J Allergy Clin Immunol 88: 147–165PubMedCrossRefGoogle Scholar
  131. 131.
    Johnson M (1996) Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids. J Allergy Clin Immunol 97: 169–176PubMedCrossRefGoogle Scholar
  132. 132.
    Chaplin MD, Rooks W, Svenson EW, Couper WC, Nerenberg C, Chu NI (1980) Flunisotide metabolism and dynamics of a metabolite. Clin Pharmacol Ther 27: 402–413PubMedCrossRefGoogle Scholar
  133. 133.
    Ryrfeldt A, Andersson P, Edsbacker S, Tonnesson M, Davies D, Pauwels R (1982) Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis 63 (Supple 122): 86–95Google Scholar
  134. 134.
    Mollman H, Rohdewald P, Schmidt EW, Salomon V, Derendorf H (1985) Pharmacokinetics of triamcinolone acetonide and its phosphate ester. Eur J Clin Pharmacol 29: 85–89CrossRefGoogle Scholar
  135. 135.
    Harding SM (1990) The human pharmacology of fluticasone diproprionate. Resp Med 84 (Suppl A): 25–29CrossRefGoogle Scholar
  136. 136.
    Toogood JH, Baskerville JC, Jennings B, Lefcoe NM, Johansson SA (1982) Influence of dosing frequency and schedule on the response of chronic asthmatics to the aerosol steroid budesonide. J Allergy Clin Immunol 70: 288–298PubMedCrossRefGoogle Scholar
  137. 137.
    Meltzer EO, Kemp JP, Welch MJ, Orgel HA (1985) Effect of dosing schedule on efficacy of beclomethasone diproprionate aerosol in chronic asthma. Am Rev Respir Dis 131: 732–736PubMedGoogle Scholar
  138. 138.
    Malo J, Cartier A, Merland N, Ghezzo H, Burke A, Morris J, Jennings BH (1989) Four-times-a-day dosing frequency is better than twice-a-day regimen in subjects requiring a high-dose inhaled steroid, budesonide, to control moderate to severe asthma. Am Rev Respir Dis 140: 624–628PubMedGoogle Scholar
  139. 139.
    Jones AH, Langdon CG, Lee PS, Lingham SA, Nankani JP, Follows RMA, Tollemar U, Richardson PDI (1994) Pulmicort Turbohaler once daily as initial prophylactic therapy for asthma. Resp Med 88: 293–299CrossRefGoogle Scholar
  140. 140.
    Toogood JA, Jennings B, Greenway RW, Chung L (1980) Candidiasis and dysphonia complicating beclomethasone treatment of asthma. J Allergy Clin Immunol 65: 145–153PubMedCrossRefGoogle Scholar
  141. 141.
    Williamson IJ, Matusiewicz SP, Brown PH, Greening AP, Crompton GK (1995) Frequency of voice problems and cough in patients using pressurised aerosol inhaled steroid preparations. Eur Resp J 8: 590–592Google Scholar
  142. 142.
    Selroos O, Backman R, Forsen KO, Lofroos AB, Niemsto M, Pietinalho A, Aikas C, Riska H (1994) Local side-effects during 4-year treatment with inhaled corticosteroids — a comparison between pressurized metered dose inhalers and Turbuhaler. Allergy 49: 888–890PubMedCrossRefGoogle Scholar
  143. 143.
    Brogden RN, Heel RC, Speight TM, Avery GS (1984) Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis. Drugs 28: 99–126PubMedCrossRefGoogle Scholar
  144. 144.
    Brogden RN, McTavish D. Budesonide (1992) An updated review of its pharmacological properties and therapeutic efficacy in asthma and rhinitis. Drugs 44: 375–407PubMedCrossRefGoogle Scholar
  145. 145.
    Engel T, Heinig JH, Mailing H-J, Scharing B, Nikander K, Masden F (1989) Clinical comparison of inhaled budesonide delivered either by pressurized metered dose inhaler or Turbuhaler. Allergy 44: 220–225PubMedCrossRefGoogle Scholar
  146. 146.
    Barnes PJ, Pedersen S, Busse WW (1998) Efficacy and safety of inhaled corticosteroids: an update. Am J Respir Crit Care Med 157: S1–S53PubMedGoogle Scholar
  147. 147.
    Selroos O, Halme M (1991) Effect of a Volumatic spacer and mouth rinsing on systemic absorption of inhaled corticosteroids from a metered-dose inhaler and dry powder inhaler. Thorax 46: 891–894PubMedCrossRefGoogle Scholar
  148. 148.
    Thorsson L, Edsbäcker S, Conradson T (1994) Lung deposition of budesonide from Turbohaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur Resp J 7: 1839–1844CrossRefGoogle Scholar
  149. 149.
    Brown PH, Blundell G, Greening AP, Crompton GK (1992) High dose inhaled corticosteroids and the cortisol induced response to acute severe asthma. Respir Med 86: 495–497PubMedCrossRefGoogle Scholar
  150. 150.
    Holt PR, Lowndes DW, Smithies E, Dixon GT (1990) The effect of an inhaled steroid on the hypothalamic-pituitary-adrenal axis: which tests should be used? Clin Exp Allergy 20: 145–149PubMedCrossRefGoogle Scholar
  151. 151.
    Barnes PJ, Pedersen S (1993) Efficacy and safety of inhaled steroids in asthma. Am Rev Respir Dis 148: S1–S26PubMedGoogle Scholar
  152. 152.
    Löfdahl CG, Meilstrand T, Svedmyr N (1989) Glucocorticosteroids and asthma — studies of resistance and systemic effects of glucocorticosteroids. Eur J Resp Dis 65 (Suppl 130): 69–79Google Scholar
  153. 153.
    Pedersen S, Fuglsang G (1988) Urine cortisol excretion in children treated with high doses of inhaled corticosteroids a comparison of budesonide and beclomethasone. Eur Resp J 1: 433–435Google Scholar
  154. 154.
    Clark DJ, Lipworth BJ (1997) Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients. Thorax 52: 55–58PubMedCrossRefGoogle Scholar
  155. 155.
    Brown PH, Matusiewicz SP, Shearing C, Tibi L, Greening AP, Crompton GK (1993) Systemic effects of high dose inhaled steroids: comparison of beclomethasone diproprionate and budesonide in healthy subjects. Thorax 48: 967–973PubMedCrossRefGoogle Scholar
  156. 156.
    Sly RM, Imseis M, Frazer M et al (1978) Treatment of asthma in children with triamcinolone acetonide aerosol. J Allergy Clin Immunol 62: 76–82PubMedCrossRefGoogle Scholar
  157. 157.
    Placcentini G, Sette L, Peroni DG, Bonizatto C, Bonetti S, Boner AL (1990) Double blind evaluation of effectiveness and safety of flunisolide aerosol for treatment of bronchial asthma in children. Allergy 45: 612–616CrossRefGoogle Scholar
  158. 158.
    Fabbri L, Burge PS, Croonenburgh L, Warlies F, Weeke B, Ciaccia A, Parker C (1993) Comparison of fluticasone proprionate with beclomethasone diproprionate in moderate to severe asthma treated for one year. Thorax 48: 817–823PubMedCrossRefGoogle Scholar
  159. 159.
    Prahl P (1991) Adrenocortical suppression following treatment with beclomethasone and budesonide. Clin Exp Allergy 21: 145–146PubMedCrossRefGoogle Scholar
  160. 160.
    Bisgaard H, Damkjaer Nielsen M, Andersen B et al (1988) Adrenal function in children with bronchial asthma treated with beclomethasone diproprionate or budesonide. J Allergy Clin Immunol 81: 1088–1095PubMedCrossRefGoogle Scholar
  161. 161.
    Volovitz B, Amir J, Malik H, Kauschansky A, Varsano I (1993) Growth and pituitary-adrenal function in children with severe asthma treated with inhaled budesonide. New Engl J Med 329: 1703–1708PubMedCrossRefGoogle Scholar
  162. 162.
    Law CM, Honour JW, Marchant JL, Preece MA, Warner JO (1986) Nocturnal adrenal suppression in asthmatic children taking inhaled beclomethasone dipropionate. Lancet 1: 942–944PubMedCrossRefGoogle Scholar
  163. 163.
    Tabacknik E, Zadik Z (1991) Diurnal cortisol secretion during therapy with inhaled beclomethasone diproprionate in children with asthma. J Pediatr 118: 294–297CrossRefGoogle Scholar
  164. 164.
    Philip M, Aviram M, Lieberman E, Zadik Z, Giat Y, Levy J, Tal A (1992) Integrated plasma cortisol concentration in children with asthma receiving long-term inhaled corticosteroids. Pediatr Pulmonol 12: 84–89CrossRefGoogle Scholar
  165. 165.
    Hosking DJ (1993) Effect of corticosteroids on bone turnover. Resp Med 87 (Suppl A): 15–21CrossRefGoogle Scholar
  166. 166.
    Packe GE, Douglas JG, MacDonald AF, Robins SP, Reid DM (1992) Bone density in asthmatic patients taking high dose inhaled beclomethasone dipropionate and intermittent systemic steroids. Thorax 47: 414–417PubMedCrossRefGoogle Scholar
  167. 167.
    König P, Hillman L, Cervantes CI (1993) Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate. J Pediatr 122: 219–226PubMedCrossRefGoogle Scholar
  168. 168.
    Ali NJ, Capewell S, Ward MJ (1991) Bone turnover during high dose inhaled corticosteroid treatment. Thorax 46: 160–164PubMedCrossRefGoogle Scholar
  169. 169.
    Wolthers OD, Pedersen S (1993) Bone turnover in asthmatic children treated with oral prednisolone or inhaled budesonide. Paediatr Pulmonol 16: 341–346CrossRefGoogle Scholar
  170. 170.
    Herrala J, Puolijoki H, Impivaara O, Liippo K, Tala E, Nieminen MM (1994) Bone mineral density in asthmatic women on high dose inhaled beclomethasone dipropionate. Bone 15: 621–623PubMedCrossRefGoogle Scholar
  171. 171.
    Toogood JH, Baskerville JC, Markov AE, Hodsman AB, Fraher LJ, Jennings B, Haddad RG, Drost D (1995) Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma. J Allergy Clin Immunol 96: 157–166PubMedCrossRefGoogle Scholar
  172. 172.
    Capewell S, Reynolds S, Shuttleworth D, Edwards C, Finlay AY (1990) Purpura and dermal thinning associated with high dose inhaled corticosteroids. Br Med J 300: 1548–1551CrossRefGoogle Scholar
  173. 173.
    Mak VHF, Melchor R, Spiro S (1992) Easy bruising as a side-effect of inhaled corticosteroids. Eur Resp J 5: 1068–1074Google Scholar
  174. 174.
    Roy A, Leblanc C, Paquette L, Ghezzo H, Cote J, Cartier A, Malo J (1996) Skin bruising in asthmatic subjects treated with high does of inhaled steroids: frequency and association with adrenal function. Eur Respir J 9: 226–231PubMedCrossRefGoogle Scholar
  175. 175.
    Toogood JH, Markov AE, Baskerville J, Dyson C (1993) Association of ocular cataracts with inhaled and oral steroid therapy during long term treatment for asthma. J Allergy Clin Immunol 91: 571–579PubMedCrossRefGoogle Scholar
  176. 176.
    Simons FER, Persaud MP, Gillespie CA, Cheang M, Shuckett EP (1993) Absence of posterior subcapsular cataracts in young patients treated with inhaled glucocorticoids. Lancet 342: 736–738Google Scholar
  177. 177.
    Garbe E, LeLorier J, Boivin J, Suissa S (1997) Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angel glaucoma. JAMA 227: 722–727CrossRefGoogle Scholar
  178. 178.
    Russell G (1993) Asthma and growth. Arch Dis Child 69: 695–698PubMedCrossRefGoogle Scholar
  179. 179.
    Balfour-Lynn L (1986) Growth and childhood asthma. Arch Dis Child 61: 1049–1055PubMedCrossRefGoogle Scholar
  180. 180.
    Ninan T, Russell G (1992) Asthma, inhaled corticosteroid treatment and growth. Arch Dis Child 67: 703–705PubMedCrossRefGoogle Scholar
  181. 181.
    Tinkelman DG, Reed CE, Nelson HS, Offord KP (1993) Aerosol beclomethasone dipropionate compared with theophylline as primary treatment of chronic, mild to moderately severe asthma in children. Pediatr 92: 64–77Google Scholar
  182. 182.
    Doull IJ, Freezer NJ, Holgate ST (1995) Growth of prepubertal children with mild asthma treated with inhaled beclomethasone dipropionate. Am J Respir Crit Care Med 151: 1715–1719PubMedGoogle Scholar
  183. 183.
    Allen DB, Mullen M, Mullen B (1994) A meta-analysis of the effects of oral and inhaled corticosteroids on growth. J Allergy Clin Immunol 93: 967–976PubMedCrossRefGoogle Scholar
  184. 184.
    Wolthers OD, Pedersen S (1993) Growth in asthmatic children treated with budesonide. Pediatr 90: 517–518Google Scholar
  185. 185.
    Wolthers O, Pedersen S (1993) Short term growth during treatment with inhaled fluticasone diproprionate and beclomethasone diproprionate. Arch Dis Child 68: 673–676PubMedCrossRefGoogle Scholar
  186. 186.
    Ebden P, Jenkins A, Houston G, Davies BH (1986) Comparison of two high-dose corticosteroid aerosol treatments, beclomethasone dipropionate (1500 mcg/day) and budesonide (1600 mcg/day) for chronic asthma. Thorax 41: 869–874PubMedCrossRefGoogle Scholar
  187. 187.
    Turpeinen M, Sorva R, Juntungen-Backman K (1991) Changes in carbohydrate and lipid metabolism in children with asthma inhaling budesonide. J Allergy Clin Immunol 88: 384–389PubMedCrossRefGoogle Scholar
  188. 188.
    Kruszynska YT, Greenstone M, Home PD (1987) Effect of high dose inhaled beclomethasone diproprionate on carbolydate and lipid metabolism in normal subjects. Thorax 42: 881–884PubMedCrossRefGoogle Scholar
  189. 189.
    Kiviranta K, Turpeinen M (1993) Effect of eight months of inhaled beclomethasone diproprionate and budesonide on carbohydrate metabolism in adults with asthma. Thorax 48: 974–978PubMedCrossRefGoogle Scholar
  190. 190.
    Toogood JH, Baskerville J, Jennings B (1984) Use of spacers to facilitate inhaled corticosteroid treatment of asthma. Am Rev Respir Dis 129: 723–729PubMedGoogle Scholar
  191. 191.
    Barnes PJ (1996) Inhaled glucocorticoids: new developments relevant to updating the Asthma Management Guidelines. Resp Med 90: 379–384CrossRefGoogle Scholar
  192. 192.
    Otulana BA, Varma N, Bullock A, Higenbottam T (1992) High dose nebulized steroid in the treatment of chronic steroid-dependent asthma. Resp Med 86: 105–108CrossRefGoogle Scholar
  193. 193.
    Greening AP, Ind PW, Northfield M, Shaw G (1994) Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 344: 219–224PubMedCrossRefGoogle Scholar
  194. 194.
    Woolcock AJ, Barnes PJ (1996) Asthma: the important questions-part 3. Am J Respir Crit Care Med 153: S1–S31Google Scholar
  195. 195.
    Evans DJ, Taylor DA, Zetterstrom O, Chung KF, O’Connor BJ, Barnes PJ (1997) A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. New Engl J Med 337: 1412–1418PubMedCrossRefGoogle Scholar
  196. 196.
    Rutten-van Molken MPMH, van Doorslaer EKA, Jansen MCC, Kerstjens HAM, Rutten FFH (1995) Costs and effects of inhaled coricosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 151: 975–982Google Scholar
  197. 197.
    Barnes PJ, Jonsson B, Klim J (1996) The costs of asthma. Eur Respir J 9: 636–642PubMedCrossRefGoogle Scholar
  198. 198.
    van Schayk CP, Dompeling E, Rutten MP, Folgering H, van den Boom G, van Weel C (1995) The influence of an inhaled steroid on quality of life in patients with asthma or COPD. Chest 107: 1199–1205CrossRefGoogle Scholar
  199. 199.
    O’Driscoll BR, Kalra S, Wilson M, Pickering CAC, Caroll KB, Woodcock AA (1993) Double blind trial of steroid tapering in acute asthma. Lancet 341: 324–327PubMedCrossRefGoogle Scholar
  200. 200.
    Beam WR, Ballard RD, Martin RJ (1992) Spectrum of corticosteroid sensitivity in nocturnal asthma. Am Rev Respir Dis 145: 1082–1086PubMedCrossRefGoogle Scholar
  201. 201.
    McLeod DT, Capewell SJ, Law J, MacLaren W, Seaton A (1985) Intramuscular triamcinolone acetamide in chronic severe asthma. Thorax 40: 840–845PubMedCrossRefGoogle Scholar
  202. 202.
    Ogirala RG, Aldrich TK, Prezant DJ, Sinnett MJ, Enden JB, Williams MH (1991) High dose intramuscular triamcinolone in severe life-threatening asthma. New Engl J Med 329: 585–589CrossRefGoogle Scholar
  203. 203.
    Grandordy B, Beilmatoug N, Morelle A, De Lauture D, Marac J (1987) Effect of betamethasone on airway obstruction and bronchial response to salbutamol in prednisolone resistant asthma. Thorax 42: 65–71PubMedCrossRefGoogle Scholar
  204. 204.
    Hill SJ, Tattersfield AE (1995) Corticosteroid sparing agents in asthma. Thorax 50: 577–582PubMedCrossRefGoogle Scholar
  205. 205.
    Mullarkey MF, Lammert JK, Blumenstein BA (1990) Long-term methotrexate treatment in corticosteroid-dependent asthma. Ann Intern Med 112: 5777–581Google Scholar
  206. 206.
    Shiner RJ, Nunn AJ, Chung KF, Geddes DM (1990) Randomized, double-blind, placebo-controlled trial of methotrexate in steroid-dependent asthma. Lancet 336: 137–140PubMedCrossRefGoogle Scholar
  207. 207.
    Nierop G, Gijzel WP, Bel EH, Zwinderman AH, Dijkman JH (1992) Auranofin in the treatment of steroid dependent asthma: a double blind study. Thorax 47: 349–354PubMedCrossRefGoogle Scholar
  208. 208.
    Alexander AG, Barnes NC, Kay AB (1992) Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. Lancet 339: 324–328PubMedCrossRefGoogle Scholar
  209. 209.
    Szczeklik A, Nizankowska E, Dworski R, Domagala B, Pinis G (1991) Cyclosporin for steroid-dependent asthma. Allergy 46: 312–315PubMedCrossRefGoogle Scholar
  210. 210.
    Nelson HS, Hamilos DL, Corsello PR, Levesque NV, Buchameier AD, Bucher BL (1993) A double-blind study of troleandamycin and methylprednisolone in asthmatic patients who require daily corticosteroids. Am Rev Respir Dis 147: 398–404PubMedGoogle Scholar
  211. 211.
    British Thorac Society (1993) Guidelines on the management of asthma. Thorax 48S (Suppl): S1–S24Google Scholar
  212. 212.
    Engel T, Heinig JH (1991) Glucocorticoid therapy in acute severe asthma — a critical review. Eur Respir J 4: 881–889PubMedGoogle Scholar
  213. 213.
    Decramer M, Lacquet LM, Fagard R, Rogiers P (1995) Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med 150: 11–16Google Scholar
  214. 214.
    Bowler SD, Mitchell CA, Armstrong JG (1992) Corticosteroids in acute severe asthma: effectiveness of low doses. Thorax 47: 584–587PubMedCrossRefGoogle Scholar
  215. 215.
    Morell F, Orkiols R, de Gracia J, Curul V, Pujol A (1992) Controlled trial of intravenous corticosteroids in severe acute asthma. Thorax 47: 588–591PubMedCrossRefGoogle Scholar
  216. 216.
    Harrison BDN, Stokes TC, Hart GJ, Vaughan DA, Ali NJ, Robinson AA (1986) Need for intravenous hydrocortisone in addition to oral prednisolone in patients admitted to hospital with severe asthma without ventilatory failure. Lancet i: 181–184CrossRefGoogle Scholar
  217. 217.
    Barnes PJ, Adcock IM (1995) Steroid-resistant asthma. Q J Med 88: 455–468Google Scholar
  218. 218.
    Barnes PJ, Greening AP, Crompton GK (1995) Glucocorticoid resistance in asthma. Am J Respir Crit Care Med 152: 125S–140SGoogle Scholar
  219. 219.
    Szefler SJ, Leung DY (1997) Glucocorticoid-resistant asthma: pathogenesis and clinical implications for management. Eur Respir J 10: 1640–1647PubMedCrossRefGoogle Scholar
  220. 220.
    Schwartz HJ, Lowell FC, Melby JC (1968) Steroid resistance in bronchial asthma. Am J Int Med 69: 493–499Google Scholar
  221. 221.
    Carmichael J, Paterson IC, Diaz P, Crompton GK, Kay AB, Grant IWB (1981) Corticosteroid resistance in chronic asthma. Br Med J 282: 1419–1422CrossRefGoogle Scholar
  222. 222.
    Lane SJ, Atkinson BA, Swimanathan R, Lee TH. Hypothalamic-pituitary axis in corticosteroid-resistant asthma. Am J Respir Crit Care Med 1996 153: 1510–1514Google Scholar
  223. 223.
    Woolcock AJ (1993) Steroid resistant asthma: what is the clinical definition? Eur Respir J 6: 743–747PubMedGoogle Scholar
  224. 224.
    Leung DYM, Martin RJ, Szefler SJ, Sher ER, Ying S, Kay AB, Hamid Q (1995) Dysregulation of interleukin 4, interleukin 5, and interferon y gene expression in steroid-resistant asthma. J Exp Med 181: 33–40PubMedCrossRefGoogle Scholar
  225. 225.
    Lamberts SWJ, Kioper JW, de Jong FH (1992) Familial and iatrogenic cortisol receptor resistance. J Steroid Biochem Molec Biol 43: 385–388PubMedCrossRefGoogle Scholar
  226. 226.
    Lane SJ, Arm JP, Staynov DZ, Lee TH (1994) Chemical mutational analysis of the human glucocortiocoid receptor cDNA in glucocorticoid-resistant bronchial asthma. Am J Resp Cell Mol Biol 11: 42–48Google Scholar
  227. 227.
    Corrigan C, Brown PH, Barnes NC, Szefler SJ, Tsai J, Frew AJ, Kay AB (1991) Glucocorticoid resistance in chronic asthma. Am Rev Respir Dis 144: 1016–1025PubMedCrossRefGoogle Scholar
  228. 228.
    Lane SJ, Palmer JBD, Skidmore IF, Lee TH (1990) Corticosteroid pharmacokinetics in asthma. Lancet 336: 126SCrossRefGoogle Scholar
  229. 229.
    Goulding NJ, Podgorski MR, Hall ND, Flower RJ, Browning JL, Pepinsky RB, Maddison PJ (1989) Autoantibodies to recombinant liportin-1 in rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis 48: 843–850PubMedCrossRefGoogle Scholar
  230. 230.
    Wilkinson JR, Podgorski MR, Godolphin JL, Goulding NJ, Lee TH (1990) Bronchial asthma is not associated with auto-antibodies to lipocortin-1. Clin Exp Allergy 20: 189–192PubMedCrossRefGoogle Scholar
  231. 231.
    Chung KF, Podgorski MR, Goulding NJ, Godolphin JL, Sharland PR, O’Connor B, Flower RJ, Barnes PJ (1991) Circulating autoantibodies to recombinant lipocortin-1 in asthma. Resp Med 95: 121–124CrossRefGoogle Scholar
  232. 232.
    Brown PH, Teelucksingh S, Matusiewicz SP, Greening AP, Crompton GK, Edwards CRW (1991) Cutaneous vasoconstrictor responses to glucocorticoids in asthma. Lancet 337: 576–580PubMedCrossRefGoogle Scholar
  233. 233.
    Corrigan CJ, Brown PH, Barnes NC, Tsai J, Frew AJ, Kay AB (1991) Peripheral blood T lymphocyte activation and comparison of the T lymphocyte inhibitory effects of glucocorticoids and cyclosporin A. Am Rev Respir Dis 144: 1026–1032PubMedCrossRefGoogle Scholar
  234. 234.
    Lane SJ, Lee TH (1991) Glucocorticoid receptor characteristics in monocytes of patients with corticosteroid-resistant bronchial asthma. Am Rev Respir Dis 143: 1020–1024PubMedGoogle Scholar
  235. 235.
    Sher ER, Leung YM, Surs W, Kam JC, Zieg G, Kamada AK, Szefler SJ (1994) Steroid-resistant asthma. Cellular mechanisms contributing to inadequate response to glucocorticoid therapy. J Clin Invest 93: 33–39PubMedCrossRefGoogle Scholar
  236. 236.
    Kam JC, Szefler SJ, Surs W, Sher FR, Leung DYM (1993) Combination IL-2 and IL-4 reduces glucocorticoid-receptor binding affinity and T cell response to glucocorticoids. J Immunol 151: 3460–3466PubMedGoogle Scholar
  237. 237.
    Adcock IM, Lane SJ, Brown CA, Peters MJ, Lee TH, Barnes PJ (1995) Differences in binding of glucocorticoid receptor to DNA in steroid-resistant asthma. J Immunol 154: 3000–3005Google Scholar
  238. 238.
    Adcock IM, Lane SJ, Brown CA, Lee TH, Barnes PJ (1995) Abnormal glucocorticoid receptor/AP-1 interaction in steroid resistant asthma. J Exp Med 182: 1951–1958PubMedCrossRefGoogle Scholar
  239. 239.
    Adcock IM, Lane SJ, Barnes PJ, Lee TH (1996) Enhanced phorbol ester-induced c-Fos transcription and translation in steroid-resistant asthma. Am J Respir Crit Care Med 153: A682Google Scholar
  240. 240.
    Adcock IM, Brady H, Lim S, Karin M, Barnes PJ (1997) Increased JUN kinase activity in peripheral blood monocytes from steroid-resistant asthmatic subjects. Am J Respir Crit Care Med 155: A288Google Scholar
  241. 241.
    Rosewicz S, McDonald AR, Maddux BA, Godfine ID, Miesfeld RL, Logsden CD (1988) Mechanism of glucocorticoid receptor down-regulation by glucocorticoids. J Biol Chem 263: 2581–2584PubMedGoogle Scholar
  242. 242.
    Adcock IM, Brown CR, Shirasaki H, Barnes PJ (1994) Effects of dexamethasone on cytokine and phorbol ester stimulated c-Fos and c-Jun DNA binding and gene expression in human lung. Eur Resp J 7: 2117–2123CrossRefGoogle Scholar
  243. 243.
    Vacca A, Screpanati I, Maroder M, Petrangeli E, Frati L, Guline A (1989) Tumor promoting phorbol ester and raw oncogene expression inhibit the glucocorticoid-dependent transcription from the mouse mammary tumor virus long terminal repeat. Mol Endo 3: 1659–1665CrossRefGoogle Scholar
  244. 244.
    Peters MJ, Adcock IM, Brown CR, Barnes PJ (1995) β-Adrenoceptor agonists interfere with glucocorticoid receptor DNA binding in rat lung. Eur J Pharmacol (Molec Pharmacol Section) 289: 275–281PubMedCrossRefGoogle Scholar
  245. 245.
    Stevens DA, Barnes PJ, Adcock IM (1995) β-Agonists inhibit DNA binding of glucocorticoid receptors in human pulmonary and bronchial epithelial cells. Am J Resp Crit Care Med 151: A195Google Scholar
  246. 246.
    Peters MJ, Adcock IM, Brown CR, Barnes PJ (1993) b-Agonist inhibition of steroid-receptor DNA binding activity in human lung. Am Rev Respir Dis 147: A772Google Scholar
  247. 247.
    Wong CS, Wamedna I, Pavord ID, Tattersfield AE (1994) Effect of regular terbutaline and budesonide on bronchial reactivity to allergen challenge. Am J Resp Crit Care Med 15047: 1268–1278Google Scholar
  248. 248.
    Peters MJ, Yates DH, Chung KF, Barnes PJ (1993) β2-Agonist dose reduction: strategy and early results. Thorax 48: 1066Google Scholar

Copyright information

© Springer Basel AG 1999

Authors and Affiliations

  • Peter J. Barnes
    • 1
  1. 1.Department of Thoracic Medicine, Imperial College School of MedicineNational Heart and Lung InstituteLondonUK

Personalised recommendations